N/A N=1,439 Epidemiology of Severe Peroperative Bleeding During Scheduled Surgery
Surgery · Blood Loss
Primary: Unanticipated Bleeding — 0; 100; 0 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=33 Intraoperative Bleeding During Endoscopic Sinus Surgery
Blood Loss
Primary: Estimated Blood Loss — 78.5; 80.3 mL/h — p=0.937
N/A N=62 Phlebotomy to Prevent Blood Loss in Major Hepatic Resections
Liver Neoplasms · Hepatectomy
Primary: Total Intraoperative Blood Loss, by Measurement of Change in Hemoglobin Levels — 862; 872; 761; 872 mL
N/A N=103 SURGICEL® Powder in Controlling Mild or Moderate Parenchymal or Soft Tissue Intraoperative Bleeding in Adult Subjects
Hemorrhage
Primary: Haemostatic Success at 5 Minutes — 90 Participants
Phase 4 N=40 Effect of Tranexamic Acid on Postoperative Bleeding Following Sinus and Nasal Surgery
Chronic Sinusitis · Nasal Obstruction · Turbinate; Hypertrophy Mucous Membrane
Primary: Bleeding VAS - POD1 — 5.03; 4.82 score on a scale — p=0.8
Phase 3 N=721 A Study of Fibrocaps™ in Surgical Bleeding
Mild or Moderate Surgical Bleeding
Primary: Time to Hemostasis (TTH) for Participants Receiving Spinal Surgery — 1.0; 2.5 minutes — p=< 0.0001
N/A N=184 Platelet Inhibition and Bleeding in Patients Undergoing Emergent Cardiac Surgery
Bleeding
Primary: Calculated Blood Loss — 1996 milliters
Phase 3 N=57 Does Plasma Reduce Bleeding in Patients Undergoing Invasive Procedures
Blood Coagulation Disorders · Hemorrhage
Primary: Change in Hemoglobin Level — -0.6; -0.4 g/dL
N/A N=22 Surgicel Snow in Gynecological Surgery
Laparoscopic Hysterectomy
Primary: Change in Bleeding at Specified Time Intervals — 485.7; 199.1 seconds
Phase 2 N=48 Does Continued Use of Clopidogrel Into Surgery Cause Increased Perioperative Bleeding?
Clopidogrel
Primary: Bleeding-related Re-hospitalization — 1; 1 participants
Phase 4 N=18 Rectal Misoprostol as a Hemostatic Agent During Abdominal Myomectomy
Myomectomy; Surgical Blood Loss
Primary: Surgical Blood Loss — 761; 691 ml
N/A N=111 Unipolar vs. Bipolar Hemostasis in Total Knee Arthroplasty: A Prospective Randomized Trial
Knee Arthroplasty
Primary: Drain Output. — 776; 778 mL
N/A N=68 Comparison of Blood Product Use and Bleeding Events During and After Endoscopic or Neurosurgical Procedures in Patients With Cirrhosis and Coagulopathy
Cirrhosis · Coagulopathy
Primary: Intra-operative Blood Loss — 2000; 3000 milliliters
N/A N=234 The SURGICEL® Powder Mild or Moderate Parenchymal or Soft Tissue Intraoperative Bleeding (China Study)
Hemorrhage
Primary: Hemostatic Success at 5 Minutes — 109; 103 Participants — p=<0.0001
Phase 3 N=80 Magnesium and Intraoperative Blood Loss in Meningioma Surgery
Meningioma
Primary: Intraoperative Blood Loss — 510; 500 ml — p=0.315
Phase 2 N=242 Outcomes and Safety Trial Investigating Ecallantide's Effect on Reducing Surgical Blood Loss Volume in Subjects at High Risk of Bleeding Exposed to Cardio-pulmonary Bypass During Cardiac Surgery
Bloodloss · Surgical Procedures, Operative
Primary: Cumulative Volume of Packed Red Blood Cells Transfused — 1223.2; 623.5 mL — p=0.001
Phase 4 N=94 Study Of Tranexamic Acid For The Reduction Of Blood Loss In Patients Undergoing Major Abdominal Surgery
Biliary Tract Surgical Procedures · Pancreaticoduodenectomy · Esophagectomy
Primary: Post-operative Blood Loss — 394.3; 494.3 milliliter (mL) — p=0.460
N/A N=10 Blood Loss at the Time of First Trimester Surgical Abortion in Anticoagulated Women
Blood Loss
Primary: Volume of Intraoperative Blood Loss — 91.5; 52.2 milliliters
N/A N=242 Validating a New Method to Assess Estimated Blood Loss in the Obstetric Population
Pregnancy Complications
Primary: Clinical Estimated Blood Loss (EBL) Between Cases and Controls Using Clinical Estimate Versus Device Assessment — 800; 800 milliLiters
N/A N=90 Low Dose Peri- Operative Intra Venous Teranexamic Acid Reduces Blood Loss After Total Knee Arthroplasty: A Double Blind Randomized Placebo Controlled Clinical Trial
Knee Arthroplasty, Total
Primary: Hb Level 48 Hours After Total Knee Arthroplasty — 10.92; 10.23 gr/dL
Phase 2 N=295 Minimization of Bleeding Related Adverse Drug Events in Plastic & Reconstructive Surgery
Venous Thromboembolism · Deep Venous Thrombosis · Pulmonary Embolus
Primary: Avoidance of Under-anticoagulation (Peak aFXa <0.2 IU/mL) — 76.6; 79.9 percentage of participants
N/A N=66 Heparin Dose and Post Operative Bleeding in Cardiopulmonary Bypass Patients
Coronary Artery Disease
Primary: Chest Tube Losses — 726; 781 millilters — p=<0.1
N/A N=106 Accuracy of Blood Loss Estimation After Vaginal Delivery
Postpartum Hemorrhage
Primary: Difference in Actual Blood Volume and Estimated Blood Volume in Milliliters. — -20.8; -41.7; -53.5; -96.0 milliliters — p=<0.05
Phase 4 N=100 Prospective Evaluation of Vitagel for Reduction in Blood Loss and Pain Following Unilateral Total Knee Arthroplasty
Arthritis
Primary: Number of Patients Managed With Blood Transfusion — 0; 5 participants
N/A N=260 Effectiveness and Safety of CELSTAT for Hemostasis in Intraoperative Tissue Bleeding
Bleeding Active
Primary: Number of Participants With Hemostasis Achieved at Target Bleeding Site Within 5 Minutes After Application — 94; 109; 32; 15 Participants
N/A N=14 Blood Volume Analysis of Total Hip Arthroplasty Patients Under Hypotensive Anesthesia
Blood Volume Analysis
Primary: Change in Total Blood Volume — 487 ml
N/A N=60 A New Approach for Controlling Hemostasis During Canal Treatment
Blood Contamination of Root Canal During Endodontic Therapy
Primary: Change From Baseline in Root Canal Bleeding — 3.40; 3.73; 0.26; 3.03 millimeters — p=<.0001
N/A N=324 Prospective, Multicenter, Multidisciplinary, Controlled Clinical Investigation Evaluating the Safety and Efficacy of PerClot® Polysaccharide Hemostatic System
Blood Loss, Surgical
Primary: Number of Participants With Achievement of Hemostasis at 7 Minutes — 145; 149 Participants — p=0.005
N/A N=112 Evaluation of Thromboelastometry (ROTEM) During Spinal Surgery
Blood Loss, Surgical
Primary: Number of Participants Needing an Intraoperative Autologue Blood Product Transfusion — 24; 24 Participants
Phase 2 N=61 The Use of Tranexamic Acid to Reduce Perioperative Blood Loss During High Risk Spine Fusion Surgery
Curvature of Spine
Primary: Total Red Blood Cells Transfused in the Intraoperative Period — 1140; 1460 milliliters — p=.05